GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Dec 02, 2013

London, UK, 2 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Piper Jaffray 25th Annual Health Care Conference on Wednesday, 4 December, 2013 at 8:30 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 23 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW   Pharmaceuticals plc

(Today) + 44   20 7831 3113

Justin Gover,   Chief Executive Officer

(Thereafter) + 44 1980 557000

Stephen Schultz,   VP Investor Relations (US)

+ 1 401 500 6570

FTI   Consulting (Media Enquiries)

 

Ben Atwell /   Simon Conway / John Dineen (UK)

+ 44 20 7831 3113

Robert   Stanislaro (US)

+1 212 850 5657

Trout   Group, LLC (US investor relations)

 

Todd James / Chad   Rubin

+1 646 378 2900

               

Recent News